Alise Reicin, MD, is currently President, Global Clinical Operations, for Celgene. In this capacity, she oversees Clinical Therapeutic Areas, Statistics, Program Leadership, and Project Management. Dr. Reicin has extensive early and late clinical development experience working across a broad range of therapeutic areas including oncology and immunology.
Prior to her current position, Dr. Reicin served as Head of Global Clinical Development for the biopharmaceutical business of Merck KGAa, Darmstadt Germany. In this capacity, she oversaw Clinical Therapeutic Areas, Statistics, Evidence and Value Development and Clinical Operations.
Prior to this, Dr. Reicin served as Vice President, Project and Pipeline Leadership, Oncology Franchise at Merck (known as MSD outside the US). In this capacity, she led Merck’s PD-1 program and oversaw the initial development and filing activities worldwide, including the first approval in the US and the creation and initiation of early and late stage development plans in several different indications including Melanoma, NSCLC, Gastric Cancer, Breast Cancer, Urothelial Cancer, Hodgkin’s Lymphoma, Head and Neck Cancer. She also managed program leaders across early and late oncology product development teams. During Dr. Reicin’s tenure at MSD, she held roles of increasing responsibility in R&D, including Vice President and Therapeutic Area Head (Bone, Respiratory, Immunology and Endocrinology); Vice President, Research & Early Development (Bone, Respiratory, Immunology and Endocrinology Franchise Integrator); Vice President, Strategic Realization Office; Vice President and Therapeutic Area Head (Clinical Immunology & Analgesia); and Head of a Transformation Task Force for late clinical development.
Prior to her positions at Merck, Dr. Reicin was a faculty member at Columbia Medical School and a physician and researcher at Columbia Presbyterian Hospital in New York. Dr. Reicin has a degree in biochemistry from Barnard College of Columbia University and received her medical degree from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with Massachusetts Institute of Technology (MIT).